Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea

Por Gerber, David E., Schiller, Joan H.
Publicado em 2013

DNA Methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer

Por Belinsky, Steven A, Schiller, Joan H, Stidley, Christine A
Publicado em 2008

Why Oncologists Should Care About Climate Change

Por Schiller, Joan H., Averbuch, Steven D., Berg, Christine D.
Publicado no JCO Oncol Pract (2020)

New molecularly targeted therapies for lung cancer

Por Sun, Sophie, Schiller, Joan H., Spinola, Monica, Minna, John D.
Publicado em 2007

Does Histology Predict Survival of Advanced Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy? An Analysis of the Eastern Cooperative Oncology Group Study...

Por Hoang, Tien, Dahlberg, Suzanne E., Schiller, Joan H., Johnson, David H.
Publicado no Lung Cancer (2013)

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4...

Por Dahlberg, Suzanne E., Sandler, Alan B., Brahmer, Julie R., Schiller, Joan H., Johnson, David H.
Publicado em 2010

Prognostic Models to Predict Survival in Non-Small Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Por Hoang, Tien, Dahlberg, Suzanne E., Sandler, Alan B., Brahmer, Julie R., Schiller, Joan H., Johnson, David H.
Publicado em 2012

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner

Por Frink, Robin E., Peyton, Michael, Schiller, Joan H., Gazdar, Adi F., Shay, Jerry W., Minna, John D.
Publicado no Oncotarget (2016)

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 350...

Por Amann, Joseph M., Lee, Ju-Whei, Roder, Heinrich, Brahmer, Julie, Gonzalez, Adriana, Schiller, Joan H., Carbone, David P.
Publicado em 2010

A double-blind randomized discontinuation phase II study of sorafenib (BAY 43-9006) in previously treated non-small cell lung cancer patients: Eastern Cooperative Oncology Group st...

Por Wakelee, Heather A., Lee, Ju-Whei, Hanna, Nasser H., Traynor, Anne M., Carbone, David P., Schiller, Joan H.
Publicado em 2012

Stigma among patients with lung cancer: A patient-reported measurement model

Por Hamann, Heidi A., Ostroff, Jamie S., Marks, Emily G., Gerber, David E., Schiller, Joan H., Craddock Lee, Simon J.
Publicado em 2013

Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who w...

Por Hanna, Nasser H., Dahlberg, Suzanne E., Kolesar, Jill, Aggarwal, Charu, Hirsch, Fred R., Ramalingam, Suresh S., Schiller, Joan H.
Publicado no Cancer (2015)

Attitudes and Stereotypes in Lung Cancer versus Breast Cancer

Por Sriram, N., Mills, Jennifer, Lang, Edward, Dickson, Holli K., Hamann, Heidi A., Nosek, Brian A., Schiller, Joan H.
Publicado no PLoS One (2015)

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

Por Horn, Leora, Dahlberg, Suzanne E., Sandler, Alan B., Dowlati, Afshin, Moore, Dennis F., Murren, John R., Schiller, Joan H.
Publicado em 2009

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-Small-Cell Lung Cancer Treated with or without Bevacizumab in Combination with Pac...

Por Brahmer, Julie R., Dahlberg, Suzanne E., Gray, Robert J., Schiller, Joan H., Perry, Michael C., Sandler, Alan, Johnson, David H.
Publicado em 2011

The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer

Por kolesar, Jill M., Dahlberg, Suzanne E., Marsh, Sharon, Mcleod, Howard L., Johnson, David H., Keller, Steven M., Schiller, Joan H.
Publicado em 2011

Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: T...

Por Hoang, Tien, Dahlberg, Suzanne E., Schiller, Joan H., Mehta, Minesh P., Fitzgerald, Thomas J., Belinsky, Steven A., Johnson, David H.
Publicado em 2012

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer T...

Por Sandler, Alan B., Schiller, Joan H., Gray, Robert, Dimery, Isaiah, Brahmer, Julie, Samant, Meghna, Wang, Lisa I., Johnson, David H.
Publicado em 2009

Body Mass Index and its Association with Clinical Outcomes for Advanced Non-Small Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

Por Dahlberg, Suzanne E., Schiller, Joan H., Bonomi, Philip B., Sandler, Alan B., Brahmer, Julie R., Ramalingam, Suresh S., Johnson, David H.
Publicado em 2013

Interferon Alpha Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC): An Eastern Cooperative Oncology Group Study (E6501)

Por Pillai, Rathi N., Aisner, Joseph, Dahlberg, Suzanne E., Rogers, John S., DiPaola, Robert S., Aisner, Seena, Ramalingam, Suresh S., Schiller, Joan H.
Publicado no Cancer Chemother Pharmacol (2014)